Effects of a tacrine-8-hydroxyquinoline hybrid (IQM-622) on Aβ accumulation and cell death: Involvement in hippocampal neuronal loss in Alzheimer's disease

Neurobiology of Disease

Volumn 46, Issue 3, 2012, Pages 682-691

  Antequera, Desiree ^a,b   Bolos, Marta ^a,b   Spuch, Carlos ^a,b,c   Pascual, Consuelo ^a,b   Ferrer, Isidro ^b,d   Fernandez Bachiller, María Isabel ^e   Rodríguez Franco, María Isabel ^e   Carro, Eva ^a,b  

^a Instituto de Investigación Hospital 12 de Octubre ^*  (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e INSTITUTO DE QUÍMICA MÉDICA   (Spain)

Author keywords

A degradation; Acetylcholinesterase inhibitors; Alzheimer's disease; Domoic acid; Neuroprotection; Transgenic mice

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; DOMOIC ACID; IQM 622; NEUROPROTECTIVE AGENT; TACRINE 8 HYDROXYQUINOLINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DENTATE GYRUS; DRUG MECHANISM; EMBRYO; ENZYME INHIBITION; HIPPOCAMPAL CA1 REGION; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NERVE CELL; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ASTROCYTES; CELL DEATH; CELLS, CULTURED; HIPPOCAMPUS; HUMANS; HYDROXYQUINOLINES; IMMUNOHISTOCHEMISTRY; MICE; MICE, TRANSGENIC; NEURONS; NEUROPROTECTIVE AGENTS; PRESENILIN-1; TACRINE;

EID: 84860838525     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.03.009     Document Type: Article

References (62)

1. Adlard P.A., Cherny R.A., Finkelstein D.I., Gautier E., Robb E., Cortes M., Volitakis I., Liu X., Smith J.P., Perez K., Laughton K., Li Q.X., Charman S.A., Nicolazzo J.A., Wilkins S., Deleva K., Lynch T., Kok G., Ritchie C.W., Tanzi R.E., Cappai R., Masters C.L., Barnham K.J., Bush A.I. Rapid restoration of cognition in Alzheimer's Transgenic Mice with 8-hydroxy quinoline analog is associated with decreased intersticial A[U+F062]. Neuron 2008, 59:43-55.
2. Adlard P.A., Bica L., White A.R., Nurjono M., Filiz G., Crouch P.J., Donnelly P.S., Cappai R., Finkelstein D.I., Bush A.I. Metal ionophore treatment restores dendritic spine density and synaptic protein levels in a mouse model of Alzheimer's disease. PLoS One 2011, 6:e17669.
3. Alvira-Botero X., Pérez-Gonzalez R., Spuch C., Vargas T., Antequera D., Garzón M., Bermejo-Pareja F., Carro E. Megalin interacts with APP and the intracellular adapter protein FE65 in neurons. Mol. Cell. Neurosci. 2010, 45:306-315.
4. Ananth C., Gopalakrishnakone P., Kaur C. Protective role of melatonin in domoic acid-induced neuronal damage in the hippocampus of adult rats. Hippocampus 2003, 13:375-387.
5. Arce M.P., Rodríguez-Franco M.I., González-Muñoz G.C., Pérez C., López B., Villarroya M., López M.G., García A.G., Conde S. Neuroprotective and Cholinergic Properties of Multifunctional Glutamic Acid Derivatives for the Treatment of Alzheimer's Disease. J. Med. Chem. 2009, 52:7249-7257.
6. Ben-Ari Y., Cossart R. Kainate, a double agent that generates seizures: two decades of progress. Trends Neurosci. 2000, 23:580-587.
7. Bobinski M., Wegiel J., Tarnawski M., Bobinski M., Reisberg B., de Leon M.J., Miller D.C., Wisniewski H.M. Relationships between regional neuronal loss and neurofibrillary changes in the hippocampal formation and duration and severity of Alzheimer disease. J. Neuropathol. Exp. Neurol. 1997, 56:414-420.
8. Bolognesi M.L., Cavalli A., Melchiorre C. Memoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease. Neurotherapeutics 2009, 6:152-162.
9. Borchelt D.R., Ratovitski T., van Lare J., Lee M.K., Gonzales V., Jenkins N.A., Copeland N.G., Price D.L., Sisodia S.S. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997, 19:939-945.
10. Bush A.I. Drug development based on the metals hypothesis of Alzheimer's disease. J. Alzheimers Dis. 2008, 15:223-240.
11. Carro E., Trejo J.L., Busiguina S., Torres-Aleman I. Circulating insulin-like growth factor I mediates the protective effects of physical exercise against brain insults of different etiology and anatomy. J. Neurosci. 2001, 21:5678-5684.
12. Carro E., Trejo J.L., Gomez-Isla T., LeRoith D., Torres-Aleman I. Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat. Med. 2002, 8:1390-7139.
13. Castro A., Martínez A. Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors. Curr. Pharm. Des. 2006, 12:4377-4387.
14. Castro A., Conde S., Rodríguez-Franco M.I., Martínez A. Non-cholinergic pharmacotherapy approaches to the future treatment of Alzheimer's disease. Mini Rev. Med. Chem. 2002, 2:37-50.
15. Cavalli A., Bolognesi M.L., Capsoni S., Andrisano V., Bartolini M., Margotti E., Cattaneo A., Recanatini M., Melchiorre C. A small molecule targeting the multifactorial nature of Alzheimer's disease. Angew. Chem. Int. Ed. 2007, 46:3689-3692.
16. Cavalli A., Bolognesi M.L., Minarini A., Rosini M., Tumiatti V., Recanatini M., Melchiorre C. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem. 2008, 51:347-372.
17. Cherny R.A., Atwood C.S., Xilinas M.E., Gray D.N., Jones W.D., McLean C.A., Barnham K.J., Volitakis I., Fraser F.W., Kim Y., Huang X., Goldstein L.E., Moir R.D., Lim J.T., Beyreuther K., Zheng H., Tanzi R.E., Masters C.L., Bush A.I. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001, 30:665-676.
18. Chong Y.H., Suh Y.H. Amyloidogenic processing of Alzheimer's amyloid precursor protein in vitro and its modulation by metal ions and tacrine. Life Sci. 1996, 59:545-557.
19. De Ferrari G.V., Canales M.A., Shin I., Weiner L.M., Silman I., Inestrosa N.C. A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. Biochemistry 2001, 40:10447-10457.
20. Dietrich M.O., Spuch C., Antequera D., Rodal I., de Yébenes J.G., Molina J.A., Bermejo F., Carro E. Megalin mediates the transport of leptin across the blood-CSF barrier. Neurobiol. Aging 2008, 29:902-912.
21. Dong J., Atwood C.S., Anderson V.E., Siedlak S.L., Smith M.A., Perry G., Carey P.R. Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry 2003, 42:2768-2773.
22. Faux N.G., Ritchie C.W., Gunn A., Rembach A., Tsatsanis A., Bedo J., Harrison J., Lannfelt L., Blennow K., Zetterberg H., Ingelsson M., Masters C.L., Tanzi R.E., Cummings J.L., Herd C.M., Bush A.I. PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses. J. Alzheimers Dis. 2010, 20:509-516.
23. Fernández-Bachiller M.I., Pérez C., Campillo N.E., Páez J.A., González-Muñoz G.C., Usán P., García-Palomero E., López M.G., Villarroya M., García A.G., Martínez A., Rodríguez-Franco M.I. Tacrine - Melatonin Hybrids as Multifunctional Agents for Alzheimer's Disease, with Cholinergic, Antioxidant, and Neuroprotective Properties. Chem. Med. Chem. 2009, 4:828-841.
24. Fernández-Bachiller M.I., Pérez C., González-Muñoz G.C., Conde S., López M.G., Villarroya M., García A.G., Rodríguez-Franco M.I. Novel Tacrine - 8-Hydroxyquinoline Hybrids as Multifunctional Agents for the Treatment of Alzheimer's Disease, with Neuroprotective, Cholinergic, Antioxidant, and Copper-Complexing Properties. J. Med. Chem. 2010, 53:4927-4937.
25. Fu H., Li W., Lao Y., Luo J., Lee N.T., Kan K.K., Tsang H.W., Tsim K.W., Pang Y., Li Z., Chang D.C., Li M., Han Y. Bis(7)-tacrine attenuates beta amyloid-induced neuronal apoptosis by regulating L-type calcium channels. J. Neurochem. 2006, 98:1400-1410.
26. Funato H., Yoshimura M., Yamazaki T., Saido T.C., Ito Y., Yokofujita J., Okeda R., Ihara Y. Astrocytes containing amyloid beta-protein (Abeta)-positive granules are associated with Abeta40-positive diffuse plaques in the aged human brain. Am. J. Pathol. 1998, 152:983-992.
27. García-Palomero E., Muñoz P., Usan P., Garcia P., De Austria C., Valenzuela R., Rubio L., Medina M., Martínez A. Potent β-Amyloid Modulators. Neurodegener Dis 2008, 5:153-156.
28. González-Muñoz G.C., Arce M.P., Pérez C., Villarroya M., López M.G., García A.G., Conde S., Rodríguez-Franco M.I. Old phenothiazine and dibenzothiadiazepine derivatives for tomorrow's neuroprotective therapies against neurodegenerative diseases. Eur. J. Med. Chem. 2010, 45:6152-6158.
29. González-Muñoz G.C., Arce M.P., López B., Pérez C., Romero A., del Barrio L., Martín-de-Saavedra M.D., Egea J., León R., Villarroya M., López M.G., García A.G., Conde S., Rodríguez-Franco M.I. N-Acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease. Eur. J. Med. Chem. 2011, 46:2224-2235.
30. Grossberg G.T., Pejović V., Miller M.L., Graham S.M. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2009, 27:164-172.
31. Hedberg M.M., Clos M.V., Ratia M., Gonzalez D., Lithner C.U., Camps P., Muñoz-Torrero D., Badia A., Giménez-Llort L., Nordberg A. Effect of huprine X on β-amyloid, synaptophysin and α7 neuronal nicotinic acetylcholine receptors in the brain of 3xTg-AD and APPswe transgenic mice. Neurodegener Dis 2010, 7:379-388.
32. Holzgrabe U., Kapková P., Alptüzüun V., Scheiber J., Kugelmann E. Targeting acetylcholinesterase to treat neurodegeneration. Expert Opin. Ther. Targets 2007, 11:161-179.
33. Huang X., Moir R., Tanzi R.E., Bush A.I., Rogers J.T. Redox-active metals, oxidative stress, and Alzheimer's disease pathology. Ann. NY Acad. Sci. 2004, 1012:153-163.
34. Inestrosa N.C., Dinamarca M.C., Alvarez A. Amyloid-cholinesterase interactions. Implications for Alzheimer's disease. FEBS J. 2008, 275:625-632.
35. Jiang M., Chen G. Ca2+ regulation of dynamin-independent endocytosis in cortical astrocytes. J. Neurosci. 2009, 29:8063-8074.
36. Klein W.L. Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int. 2002, 41:345-352.
37. Lannfelt L., Blennow K., Zetterberg H., Batsman S., Ames D., Harrison J., Masters C.L., Targum S., Bush A.I., Murdoch R., Wilson J., Ritchie C.W. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2008, 7:779-786. PBT2-201-EURO study group.
38. Lee I.H., Cao L., Mostoslavsky R., Lombard D.B., Liu J., Bruns N.E., Tsokos M., Alt F.W., Finkel T. A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:3374-3379.
39. Li W., Pi R., Chan H.H., Fu H., Lee N.T., Tsang H.W., Pu Y., Chang D.C., Li C., Luo J., Xiong K., Li Z., Xue H., Carlier P.R., Pang Y., Tsim K.W., Li M., Han Y. Novel dimeric acetylcholinesterase inhibitor bis7-tacrine, but not donepezil, prevents glutamate-induced neuronal apoptosis by blocking N-methyl-D-aspartate receptors. J. Biol. Chem. 2005, 18:18179-18188.
40. Mirra S.S., Gearing M., McKeel D.W., Crain B.J., Hughes J.P., van Belle G., Heyman A. Interlaboratory comparison of neuropathology assessments in Alzheimer's disease: a study of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD). J. Neuropathol. Exp. Neurol. 1994, 53:303-315.
41. Nishitsuji K., Hosono T., Uchimura K., Michikawa M. Lipoprotein lipase is a novel amyloid beta (Abeta)-binding protein that promotes glycosaminoglycan-dependent cellular uptake of Abeta in astrocytes. J. Biol. Chem. 2011, 286:6393-6401.
42. Park M.H., Lee S.J., Byun H.R., Kim Y., Oh Y.J., Koh J.Y., Hwang J.J. Clioquinol induces autophagy in cultured astrocytes and neurons by acting as a zinc ionophore. Neurobiol. Dis. 2011, 42:242-251.
43. Price K.A., Crouch P.J., White A.R. Therapeutic treatment of AlzheimerD́s disease using metal complexing agents. Recent Pat. CNS Drug Discov. 2007, 2:180-187.
44. Qizilbash N., Whitehead A., Higgins J., Wilcock G., Schneider L., Farlow M. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration. JAMA 1998, 280:1777-1782.
45. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N. Engl. J. Med. 2010, 362:329-344.
46. Rees T., Hammond P.I., Soreq H., Younkin S., Brimijoin S. Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex. Neurobiol. Aging 2003, 24:777-787.
47. Ritchie C.W., Bush A.I., Mackinnon A., Macfarlane S., Mastwyk M., MacGregor L., Kiers L., Cherny R., Li Q.X., Tammer A., Carrington D., Mavros C., Volitakis I., Xilinas M., Ames D., Davis S., Beyreuther K., Tanzi R.E., Masters C.L. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 2003, 60:1685-1691.
48. Rodríguez-Franco M.I., Fernández-Bachiller M.I., Pérez C., Hernández-Ledesma B., Bartolomé B. Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. J. Med. Chem. 2006, 49:459-462.
49. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81:741-766.
50. Selkoe D.J., Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol. 2003, 43:545-584.
51. Shaffer L.M., Dority M.D., Gupta-Bansal R., Frederickson R.C.A., Younkin S.G., Brunden K.R. Amyloid, protein (AP) removal by neuroglial cells in culture. Neurobiol. Aging 1995, 16:737-745.
52. Smith D.A. Treatment of Alzheimer's disease in the long-term-care setting. Am. J. Health Syst. Pharm. 2009, 66:899-907.
53. Smith D.G., Cappai R., Barnham K.J. The redox chemistry of the Alzheimer's disease amyloid beta peptide. Biochim. Biophys. Acta 2007, 1768:1976-1990.
54. Spuch C., Antequera D., Fernández-Bachiller M.I., Rodríguez-Franco M.I., Carro E. A new tacrine - melatonin hybrid reduces amyloid burden and behavioral deficits in a mouse model of Alzheimer's disease. Neurotox. Res. 2010, 17:421-431.
55. Takada-Takatori Y., Kume T., Sugimoto M., Katsuki H., Sugimoto H., Akaike A. Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology 2006, 51:474-486.
56. Trejo J.L., Carro E., Torres-Aleman I. Circulating insulin-like growth factor I mediates exercise-induced increases in the number of new neurons in the adult hippocampus. J. Neurosci. 2001, 21:1628-1634.
57. Vargas T., Ugalde C., Spuch C., Antequera D., Morán M.J., Martín M.A., Ferrer I., Bermejo-Pareja F., Carro E. Abeta accumulation in choroid plexus is associated with mitochondrial-induced apoptosis. Neurobiol. Aging 2010, 31:1569-1581.
58. Velez-Pardo C., Arellano J.I., Cardona-Gomez P., Jimenez Del Rio M., Lopera F., De Felipe J. CA1 hippocampal neuronal loss in familial Alzheimer's disease presenilin-1 E280A mutation is related to epilepsy. Epilepsia 2004, 45:751-756.
59. Walsh D.M., Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004, 44:181-193.
60. Wang T.T., Zeng G.C., Li X.C., Zeng H.P. In vitro studies on the antioxidant and protective effect of 2-substituted -8-hydroxyquinoline derivatives against H(2)O(2)-induced oxidative stress in BMSCs. Chem. Biol. Drug Des. 2010, 75:214-222.
61. Watanabe K.H., Andersen M.E., Basu N., Carvan M.J., Crofton K.M., King K.A., Suñol C., Tiffany-Castiglioni E., Schultz I.R. Defining and modeling known adverse outcome pathways: Domoic acid and neuronal signaling as a case study. Environ. Toxicol. Chem. 2011, 30:9-21.
62. Wyss-Coray T., Loike J.D., Brionne T.C., Lu E., Anankov R., Yan F., Silverstein S.C., Husemann J. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat. Med. 2003, 9:453-457.